[go: up one dir, main page]

GR1010769B - Ibuprofen aqueous solution for intravenous administration - Google Patents

Ibuprofen aqueous solution for intravenous administration Download PDF

Info

Publication number
GR1010769B
GR1010769B GR20230100623A GR20230100623A GR1010769B GR 1010769 B GR1010769 B GR 1010769B GR 20230100623 A GR20230100623 A GR 20230100623A GR 20230100623 A GR20230100623 A GR 20230100623A GR 1010769 B GR1010769 B GR 1010769B
Authority
GR
Greece
Prior art keywords
aqueous solution
intravenous administration
ibuprofen
ibuprofen aqueous
cyclodextrins
Prior art date
Application number
GR20230100623A
Other languages
Greek (el)
Inventor
Ιουλια Κλεωνος Τσετη
Original Assignee
Ιουλια Κλεωνος Τσετη
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ιουλια Κλεωνος Τσετη filed Critical Ιουλια Κλεωνος Τσετη
Priority to GR20230100623A priority Critical patent/GR1010769B/en
Priority to PCT/GR2024/000014 priority patent/WO2024246565A2/en
Publication of GR1010769B publication Critical patent/GR1010769B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to formulations of stable aqueous solution of ibuprofen for use in intravenous administration, which contain water, ibuprofen or a pharmaceutically acceptable derivative thereof and one or more solubilizing agents, especially one or more basic amino acids and optionally one or more cyclodextrins.
GR20230100623A 2023-06-02 2023-07-27 Ibuprofen aqueous solution for intravenous administration GR1010769B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GR20230100623A GR1010769B (en) 2023-07-27 2023-07-27 Ibuprofen aqueous solution for intravenous administration
PCT/GR2024/000014 WO2024246565A2 (en) 2023-06-02 2024-05-31 Pharmaceutical composition comprising ibuprofen

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20230100623A GR1010769B (en) 2023-07-27 2023-07-27 Ibuprofen aqueous solution for intravenous administration

Publications (1)

Publication Number Publication Date
GR1010769B true GR1010769B (en) 2024-09-18

Family

ID=93154602

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20230100623A GR1010769B (en) 2023-06-02 2023-07-27 Ibuprofen aqueous solution for intravenous administration

Country Status (1)

Country Link
GR (1) GR1010769B (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439830B1 (en) * 2001-11-02 2005-10-19 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
CN101966147A (en) * 2010-09-27 2011-02-09 四川阳光润禾药业有限公司 Ibuprofen injection composite and preparation method thereof
CN101991540A (en) * 2009-08-27 2011-03-30 杭州赛利药物研究所有限公司 Ibuprofen injection and preparation method thereof
CN102552117A (en) * 2010-12-27 2012-07-11 成都国为医药科技有限公司 Injection containing ibuprofen and preparation method of injection
EP2635269B1 (en) * 2010-11-04 2019-05-22 AFT Pharmaceuticals Limited A combination composition
US20190343785A1 (en) * 2014-07-18 2019-11-14 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
CN114588107A (en) * 2022-04-06 2022-06-07 河北一品生物医药有限公司 Ibuprofen lysine salt injection and preparation method thereof
WO2023043207A1 (en) * 2021-09-15 2023-03-23 구주제약주식회사 Pharmaceutical composition with improved stability comprising propionic acid-based drug and stabilizer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1439830B1 (en) * 2001-11-02 2005-10-19 Cumberland Pharmaceuticals Inc. Pharmaceutical composition of 2-(4-isobutylphenyl) propionic acid
CN101991540A (en) * 2009-08-27 2011-03-30 杭州赛利药物研究所有限公司 Ibuprofen injection and preparation method thereof
CN101966147A (en) * 2010-09-27 2011-02-09 四川阳光润禾药业有限公司 Ibuprofen injection composite and preparation method thereof
EP2635269B1 (en) * 2010-11-04 2019-05-22 AFT Pharmaceuticals Limited A combination composition
CN102552117A (en) * 2010-12-27 2012-07-11 成都国为医药科技有限公司 Injection containing ibuprofen and preparation method of injection
US20190343785A1 (en) * 2014-07-18 2019-11-14 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
WO2023043207A1 (en) * 2021-09-15 2023-03-23 구주제약주식회사 Pharmaceutical composition with improved stability comprising propionic acid-based drug and stabilizer
CN114588107A (en) * 2022-04-06 2022-06-07 河北一品生物医药有限公司 Ibuprofen lysine salt injection and preparation method thereof

Similar Documents

Publication Publication Date Title
ES2244831T5 (en) Use of panthenol and / or pantothenic acid and hyaluronic acid and / or hyaluronate for the production of a pharmaceutical composition for ophthalmological application
MX2024007720A (en) Lipids for lipid nanoparticle delivery of active agents.
PL335571A1 (en) Stabilisation of acid-sensitive benzimidazoles by combining them with amino acids and cyclodextrins
DK1317419T3 (en) Cyanophenoxycarboxylic acid compounds and compositions to deliver active agents
RS54769B1 (en) Highly concentrated pharmaceutical formulations comprising anti-cd20 antibody
UY25055A1 (en) PHARMACEUTICAL FORMULATIONS CONTAINING VORICONAZOLE
GB0914287D0 (en) Compositions
AR037629A1 (en) PHARMACEUTICAL FORMULATIONS THAT INCLUDE A PLATINUM DERIVATIVE
MX2021009439A (en) Imidazo [2, 1-f] [1, 2, 4] triazin-4-amine derivatives as tlr7 agonist.
CY1110906T1 (en) PHARMACEUTICAL COMPOSITION FOR NON-ADMINISTRATION OF FENTANYL
PE20142332A1 (en) METHOD AND FORMULATION TO REDUCE THE AGGREGATION OF A MACROMOLECLE UNDER PHYSIOLOGICAL CONDITIONS
AR040709A1 (en) FORMULATION OF LAMOTRIGIN FOR LONG-TERM RELEASE AND USE OF THE SAME FOR PREPARATION
AR018862A1 (en) PHARMACEUTICAL FORMULATION OF PROLONGED RELEASE, IMPROVED FOR THE ORAL ADMINISTRATION OF NEFAZODONA OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME; ORAL DOSAGE FORM THAT UNDERSTANDS AND USE OF SUCH FORMULATION TO PREPARE THE SUCH DOSAGE FORM
EP3501532A3 (en) Therapeutic compositions including frataxin, lactoferrin, and mitochondrial energy generating enzymes, and uses thereof
ATE541562T1 (en) IBUPROFEN SUSPENSION
CY1118057T1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION
MX2021002935A (en) Csf-1r antibody formulation.
MX2019008489A (en) Treatment comprising oral or gastric administration of edaravone.
CY1109537T1 (en) Peptides and Peptide Derivatives, PREPARATION OF THESE ALSO USE THESE FOR THE PREPARATION OF THERAPEUTIC AND / OR PREVENTIVE ACTIVE ACTION
EA200300406A1 (en) PHARMACEUTICAL COMPOSITION OF DRUNEDARON FOR PARENTERAL INTRODUCTION
UA93365C2 (en) Injectable preparations of diclofenic and its pharmaceutically acceptable salts, and processes for the preparation thereof
BR9809708A (en) Pharmaceutical compositions of peptides having low solubility in physiological medium
MXPA06007510A (en) Novel drug compositions and dosage forms of topiramate.
CO5640149A2 (en) PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF ERYTHEMATE SYSTEM LUPUS
GR1010769B (en) Ibuprofen aqueous solution for intravenous administration

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20241007